Pharma and healthcare sectors face governance hurdles in AI adoption

Artificial intelligence integration within the pharmaceutical and managed care sectors is currently characterized by uneven uptake and a focus on cautious implementation. Industry leaders suggest that compliance uncertainty and the complexity of reviewing all existing applications simultaneously can lead to organizational paralysis.

To mitigate these risks, experts recommend a phased approach to adoption. In managed care, starting with “low-hanging fruit”—such as automating review summaries or internal information retrieval—allows organizations to build necessary governance and capacity before tackling more complex tasks. This progression typically moves from piloting to scaling and, eventually, optimization.

In oncology and community practice settings, risk management strategies include handling contracting and data security at the network level to protect patient and proprietary data. Experts also emphasize the necessity of physician oversight, noting that medical professionals must verify AI recommendations to catch errors, rather than accepting outputs blindly.